Central and Southern Asia vs Uganda: Percentage of bloodstream infection due to Escherichia coli resistant
Central and Southern Asia
77.3%
in 2022
Uganda
81.8%
in 2022
Central and Southern Asia rank
1st
Uganda rank
2nd
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Central and Southern Asia
- Uganda
How they compare
Uganda currently reports 81.8% against 77.3% in Central and Southern Asia, a difference of 4.5%.
That makes Uganda's figure about 1.1 times Central and Southern Asia's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Central and Southern Asia ahead.
Central and Southern Asia ranks 1st and Uganda ranks 2nd of 16 groups.
Across the 2 decades both report, Central and Southern Asia averaged higher in 1 and Uganda in 1.
Head to head by decade
| Decade | Central and Southern Asia | Uganda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 67.8% | 53.1% | 14.8% | Central and Southern Asia |
| 2020s | 75.4% | 83.4% | 7.9% | Uganda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Central and Southern Asia or Uganda?
- Uganda, at 81.8% against 77.3% in Central and Southern Asia as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Central and Southern Asia and Uganda?
- 4.5%, with Uganda ahead.
- How many years of comparable data are there for Central and Southern Asia and Uganda?
- 5 years are reported by both, from 2017 to 2022.
- How do Central and Southern Asia and Uganda rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Central and Southern Asia ranks 1st and Uganda ranks 2nd of 16 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.